Literature DB >> 19169811

A comprehensive evaluation of outcomes for inflammatory breast cancer.

Relin Yang1, Michael C Cheung, Judith Hurley, Margaret M Byrne, Youjie Huang, Teresa A Zimmers, Leonidas G Koniaris.   

Abstract

OBJECTIVE: Inflammatory breast cancer (IBC) remains the breast malignancy with the worst prognosis. We sought to determine the effects of race, socioeconomic status and treatment on outcomes for women with IBC. Study design The Florida cancer registry, inpatient and ambulatory data were queried for patients diagnosed from 1998 to 2002.
RESULTS: A total of 935 patients with IBC were identified (1.5% of all breast cancers). Overall, 83.1% were Caucasian, 13.9% African American (AA), and 15.7% Hispanic. The mean age of diagnosis was 57 years old. AA patients presented at a younger age, with higher tumor grade, and were less likely to undergo surgical therapy than their Caucasian counterparts. Median survival time (MST) for the entire cohort was 32 months, while MST for AA patients was 20 months. Patients who received chemotherapy before surgery, surgery without chemotherapy, and surgery before chemotherapy demonstrated an independent, significantly improved outcome in comparison to patients who underwent chemotherapy without surgical extirpation. The administration of radiation therapy did not demonstrate an improvement in survival. By multivariate analysis, AA race (HR = 2.19) and failure to provide surgery (HR = 2.3) were independent predictors of worse prognosis. No effect of poverty or ethnicity on outcome was observed.
CONCLUSIONS: IBC carries a poor prognosis for all patients with significantly worse outcomes for AA women. Multimodality therapy provided the best survival rates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19169811     DOI: 10.1007/s10549-009-0312-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Racial/ethnic disparities in inflammatory breast cancer survival in the Michigan Cancer Surveillance Program.

Authors:  Abdi T Gudina; Glenn Copeland; Amr S Soliman; Kelly A Hirko
Journal:  Breast Cancer Res Treat       Date:  2018-11-07       Impact factor: 4.872

2.  Inflammatory and non-inflammatory breast cancer survival by socioeconomic position in the Surveillance, Epidemiology, and End Results database, 1990-2008.

Authors:  Jennifer A Schlichting; Amr S Soliman; Catherine Schairer; David Schottenfeld; Sofia D Merajver
Journal:  Breast Cancer Res Treat       Date:  2012-06-26       Impact factor: 4.872

3.  How do I treat inflammatory breast cancer?

Authors:  Della Makower; Joseph A Sparano
Journal:  Curr Treat Options Oncol       Date:  2013-03

4.  Inflammatory breast cancer, trimodal treatment, and mortality: Does where you live matter?

Authors:  Theresa Relation; Yaming Li; James L Fisher; Allan Tsung; Bridget Oppong; Mariam F Eskander; Samilia Obeng-Gyasi
Journal:  Surgery       Date:  2021-11-30       Impact factor: 3.982

5.  Incidence of inflammatory breast cancer in women, 1992-2009, United States.

Authors:  Bryan Goldner; Carolyn E Behrendt; Hans F Schoellhammer; Byrne Lee; Steven L Chen
Journal:  Ann Surg Oncol       Date:  2013-12-24       Impact factor: 5.344

6.  Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.

Authors:  Jill K Schinkel; Shelia Hoar Zahm; Ismail Jatoi; Katherine A McGlynn; Christopher Gallagher; Catherine Schairer; Craig D Shriver; Kangmin Zhu
Journal:  Cancer Causes Control       Date:  2014-05-17       Impact factor: 2.506

7.  Pathologic Complete Response (pCR) and Survival of Women with Inflammatory Breast Cancer (IBC): An Analysis Based on Biologic Subtypes and Demographic Characteristics.

Authors:  Tithi Biswas; Charulata Jindal; Timothy L Fitzgerald; Jimmy T Efird
Journal:  Int J Environ Res Public Health       Date:  2019-01-04       Impact factor: 3.390

Review 8.  Epigenetics in Inflammatory Breast Cancer: Biological Features and Therapeutic Perspectives.

Authors:  Flavia Lima Costa Faldoni; Cláudia Aparecida Rainho; Silvia Regina Rogatto
Journal:  Cells       Date:  2020-05-08       Impact factor: 6.600

Review 9.  Differences in Breast Cancer Presentation at Time of Diagnosis for Black and White Women in High Resource Settings.

Authors:  Jo-Ann Osei-Twum; Sahra Gedleh; Aisha Lofters; Onye Nnorom
Journal:  J Immigr Minor Health       Date:  2021-03-08
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.